LYSOPHOSPHATIDIC ACID MODIFIES THE RESPONSE OF PC3 PROSTATE CANCER CELLS TO CHEMOTHERAPEUTICS

Genc G. E., Sahin E., Sahin M., Gumuslu S.

WORLD CANCER RESEARCH JOURNAL, vol.7, 2020 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 7
  • Publication Date: 2020
  • Doi Number: 10.32113/wcrj_20209_1687
  • Journal Name: WORLD CANCER RESEARCH JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Keywords: Apoptosis, Cell proliferation, Docetaxel, Estramustine, Lysophosphatidic acid, Mitoxantrone, Prostate cancer, ESTRAMUSTINE, PROLIFERATION, LPA, SURVIVAL, PHOSPHORYLATION, MECHANISMS, APOPTOSIS, MIGRATION, INVASION, RECEPTOR
  • Akdeniz University Affiliated: Yes

Abstract

Objective: Prostate cancer is the most frequently diagnosed cancer among men. Docetaxel, estramustine, and mitoxantrone are commonly used chemotherapy agents for the treatment of prostate cancer. However, lysophosphatidic acid (LPA), a biologically active glycerophospholipid derivative, induces proliferation and inhibits apoptosis in prostate cancer cells. The aim of this study was to investigate the effects of LPA against cell toxicity of docetaxel, estramustine and mitoxantrone.